TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant Strains

Benzinga Logo Benzinga By Vandana Singh
Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant Strains

Pfizer's Phase 3 study reveals a new nucleoside-modified mRNA influenza vaccine with 34.5% relative efficacy against flu strains, showing superior protection compared to traditional vaccines, though with higher short-term side effects.

Insights
PFE   positive

Demonstrated superior vaccine efficacy in clinical trials, showing potential breakthrough in flu prevention technology